ADCT — ADC Therapeutics SA
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1771910 ·
Last close
$1.05
Market Cap
$133.55M
52W High
$4.13
52W Low
$0.78
ADV30
1,269,183
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 20,851,000 | 17,236,000 | -25,245,000 | -32,968,000 | 291,496,000 | 231,008,000 | 507,873,000 |
| Dec 2025 | 23,058,000 | 21,359,000 | -18,123,000 | -6,409,000 | 323,150,000 | 261,338,000 | 508,984,000 |
| Sep 2025 | 16,427,000 | 15,225,000 | -30,326,000 | -40,966,000 | 289,758,000 | 234,738,000 | 527,941,000 |
| Jun 2025 | 18,839,000 | 18,003,000 | -30,575,000 | -56,646,000 | 321,561,000 | 264,560,000 | 520,745,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-114,550,000
Investing CF
$627,000
Financing CF
$150,091,000
CapEx
$-602,000
Dividends Paid
—
Buybacks
$-20,000
EPS Diluted TTM
$-1.05
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,668,909,000
Inventory
$4,776,000
Receivables
$31,045,000
ST Investments
—
EBIT TTM
$-84,387,000
Pretax Income TTM
$-136,139,000
Interest Exp TTM
$51,752,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$79,175,000
EBITDA
$-102,036,752
Free Cash Flow
$-74,853,000
Enterprise Value
$338,802,720
Total Cash
$231,008,000
Total Debt
$436,260,000
Shares Out
127,191,158
Trailing EPS
$-0.97
Book Value
$-1.70
ROE
—
ROA
-22.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 81,357,000 | -107,207,000 | -142,623,000 | 323,150,000 | 508,984,000 | — | -141,174,000 |
| Dec 2024 | 70,837,000 | -129,591,000 | -157,846,000 | 321,980,000 | 524,622,000 | — | -123,835,000 |
| Dec 2023 | 69,558,000 | -165,051,000 | -240,053,000 | 354,782,000 | 503,031,000 | — | -118,686,000 |
| Dec 2022 | 209,908,000 | -122,987,000 | -157,128,000 | 490,859,000 | 411,408,000 | — | -138,311,000 |
TTM Snapshot
Revenues TTM
$17,410,000
NetIncome TTM
$-36,544,000
OpCashFlow TTM
$0
Assets (Latest)
$321,980,000
Forward EPS
$-1.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NRXP | NRX Pharmaceuticals, Inc. | $134.82M | $3.15 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $132.19M | $0.94 | — |
| GNLX | GENELUX Corp | $131.83M | $2.94 | — |
| TLSA | Tiziana Life Sciences Ltd | $131.08M | $1.03 | — |
| DERM | Journey Medical Corp | $137.18M | $6.37 | — |
News headlines (Yahoo Finance, 1h cache)
Alkermes (ALKS) Reports Break-Even Earnings for Q2
2026-07-28 12:15 · Yahoo
The Cancer Therapy Strategy VERAXA Is Betting the Company On
2026-07-06 16:00 · Yahoo
ADC Therapeutics Announces New Employee Inducement Grant
2026-07-01 20:05 · Yahoo
ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
2026-06-30 11:15 · Yahoo
ADC Therapeutics (ADCT) Stock Fair Value Falls After LOTIS 5 Reshapes Analyst Views
2026-06-27 09:08 · Yahoo
ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details
2026-06-24 13:13 · Yahoo
ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities
2026-06-24 11:30 · Yahoo
ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA Data - Has The Bull Case Changed?
2026-06-08 00:17 · Yahoo
Top Midday Decliners
2026-06-04 18:25 · Yahoo
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data
2026-06-04 14:43 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.